Peptide research rarely uses a single compound in isolation. Combinations — "stacks" — are the norm in preclinical literature because biological pathways intersect. Here is a catalog of the most-studied stacks, grouped by research focus, with the rationale for each combination.
Most-studied tissue-repair combination. Complementary mechanisms: BPC-157 engages vascular/gastric repair via VEGF/NO; TB-500 drives cell migration via actin dynamics. Used in tendon, gut, muscle, cardiac preclinical models.
Skin, hair, and dermal tissue research. Adds GHK-Cu's broad gene expression modulation (4,000+ genes in cell models) to the Wolverine base. Common in dermal-focused preclinical work.
Oral tablet format. VIP (Vasoactive Intestinal Peptide) plus low-dose BPC-157 for gut-focused research protocols where oral administration is preferred.
Classic GHRH + GHS pulsatile research stack. Short-half-life GHRH analogue with selective GHS. Synergistic GH release while preserving natural pulsatile rhythm in preclinical models.
Tesamorelin's visceral adiposity research profile (40+ preclinical studies on trunk fat) combined with Ipamorelin's selective GH release. Most-cited adiposity stack.
For research protocols preferring lower Tesamorelin dose. Same pathway as 10/5mg variant.
GHRH + GHS + local IGF-1 variant research. Three-peptide combination targeting GH release plus muscle satellite cell activation pathways.
Four-peptide research stack adding GHRP-2's strong GH-release magnitude to the 3X base. For preclinical research requiring maximum GH pulse magnitude.
Multi-pathway cognitive research: Dihexa (HGF/MET synaptogenesis) + Tesofensine (triple monoamine reuptake inhibition, attention) + low-dose BPC-157 (neurovascular support). Orally administered.
For detailed cognitive peptide breakdowns, see our cognitive research guide.
Side-by-side comparison of the two most-cited tissue-repair peptides.
Three generations of incretin research peptides compared.
Three GHRH analogues, their half-lives and research contexts.
Four GH secretagogues, selectivity and off-target profiles.
Epitalon, NAD+, GHK-Cu, Thymosin Alpha-1, SS-31.
Selank, Semax, Dihexa, BDNF, PE-22-28, Tesofensine, P21.
Mechanism-grouped guide by tissue type.
Incretin, lipolysis, NNMT, mitochondrial, amylin pathways.
ERR agonist studied as exercise-mimetic research tool.
Innate immunity and inflammation research peptides.
Every test a real COA should contain, explained.
U.S. regulatory framework plainly explained.
Red flags, green signals, and the one-minute diagnostic test.
Solvent selection, technique, and stability expectations.
The BPC-157 + TB-500 combination (available as SMART MD's Wolverine Blend) is the most-cited tissue-repair stack in preclinical peptide literature. For GH axis research, CJC-1295 no-DAC + Ipamorelin is the most-cited GHRH + GHS pairing. For adiposity, Tesamorelin + Ipamorelin dominates.
Biological pathways intersect. Single-compound protocols often engage only one node of a multi-pathway process. Combinations target complementary nodes — for example, GHRH + GHS engage different receptors both upstream of GH release. In preclinical models, combinations typically produce larger magnitude effects than either compound alone at equivalent doses.
Pre-dosed blends offer dosing consistency (no pipetting error between vials) and convenience. Separately-purchased compounds offer flexibility in the exact ratios used. For researchers replicating published protocols with specific ratios not matching a pre-dosed blend, separate compounds are necessary. For standard research protocols, pre-dosed blends reduce error sources.
SMART MD's blend pricing typically reflects a modest premium (10-20%) over buying separately and combining. The premium covers pre-mixing labor, quality verification of the combined product, and the convenience factor. Bulk blend purchasers often still prefer them for dosing consistency in preclinical protocols.
Yes. All peptides and blends at SMART MD are legal to acquire for research purposes in the United States. They are classified as research-use-only compounds. See our legality guide for the full regulatory framework.
Each component peptide is verified individually by 3 independent U.S. laboratories before blending. After blending, the combined product is re-verified. Lot-specific COAs are publicly verifiable at smartmdpeptides.com/verify.
Browse every stack in our catalog with full documentation.